Clinical Toolkit

  • The most common signs and symptoms of COVID-19 are fever, cough, and shortness of breath. Less common symptoms include nausea, muscle ache, confusion, headache, and sore throat.

  • Pre-existing comorbid conditions that increase the likelihood of severe illness with COVID-19 include cardiovascular disease, diabetes, chronic respiratory disease, hypertension, cancer, and obesity.

  • It is estimated that roughly 15% of people infected with the new coronavirus will develop severe disease requiring hospitalization, and another 5% will become critically ill.

Clinical Care Toolkit Introduction

COVID-19 has created unprecedented challenges for the health care community worldwide. Recently, the emergence of novel therapeutic agents and vaccines against COVID-19 has significantly improved patient outcomes and reduced the number of individuals infected with SARS-CoV-2. In order to best serve patients, clinicians require up-to-date resources on how to utilize new therapies and the latest on changes to treatment recommendations. This Clinical Care Toolkit aims to provide health care providers with the most recent information on monoclonal antibodies, vaccines, and other agents for the treatment and prevention of COVID-19.

Click on the links below to begin exploring the COVID FRONTLINE initiative.

References

  1. Centers for Disease Control and Prevention (CDC). Learn About Age-Related Macular Degeneration. https://www.cdc.gov/features/healthyvisionmonth/index.html. Accessed March 6, 2020.
  2. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147-1159.
  3. American Macular Degeneration Foundation [AMDF website]. Wet Macular Degeneration. https://www.macular.org/wet-amd. Accessed March 6, 2020.
  4. Fine AM. Earliest symptoms caused by neovascular membranes in the macular. Arch Ophthal. 1986;104:513-514.
  5. National Institutes of Health (NIH)/National Eye Institute (NEI). AMD Data and Statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics. Accessed April 1, 2020.
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill